FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2946128073> ?p ?o ?g. }

• W2946128073 endingPage "4897" @default.
• W2946128073 startingPage "4888" @default.
• W2946128073 abstract "Abstract Purpose: Here, we report results of the first phase I study of erdafitinib, a potent, oral pan-FGFR inhibitor. Patients and Methods: Patients age ≥18 years with advanced solid tumors for which standard antineoplastic therapy was no longer effective were enrolled (NCT01703481). Parts 2 to 4 employed molecular screening for activating FGFR genomic alterations. In patients with such alterations, two selected doses/schedules identified during part 1 dose-escalation [9 mg once daily and 10 mg intermittently (7 days on/7 days off), as previously published (Tabernero JCO 2015;33:3401-8)] were tested. Results: The study included 187 patients. The most common treatment-related adverse events were hyperphosphatemia (64%), dry mouth (42%), and asthenia (28%), generally grade 1/2 severity. All cases of hyperphosphatemia were grade 1/2 except for 1 grade 3 event. Skin, nail, and eye changes were observed in 43%, 33%, and 28% of patients, respectively (mostly grade 1/2 and reversible after temporary dosing interruption). Urothelial carcinoma and cholangiocarcinoma were most responsive to erdafitinib, with objective response rates (ORR) of 46.2% (12/26) and 27.3% (3/11), respectively, in response-evaluable patients with FGFR mutations or fusions. All patients with urothelial carcinoma and cholangiocarcinoma who responded to erdafitinib carried FGFR mutations or fusions. Median response duration was 5.6 months for urothelial carcinoma and 11.4 months for cholangiocarcinoma. ORRs in other tumor types were &lt;10%. Conclusions: Erdafitinib shows tolerability and preliminary clinical activity in advanced solid tumors with genomic changes in the FGFR pathway, at two different dosing schedules and with particularly encouraging responses in urothelial carcinoma and cholangiocarcinoma." @default.
• W2946128073 created "2019-05-29" @default.
• W2946128073 creator A5000961519 @default.
• W2946128073 creator A5000978310 @default.
• W2946128073 creator A5006299989 @default.
• W2946128073 creator A5006620245 @default.
• W2946128073 creator A5021392198 @default.
• W2946128073 creator A5024388671 @default.
• W2946128073 creator A5028976895 @default.
• W2946128073 creator A5029434394 @default.
• W2946128073 creator A5031446684 @default.
• W2946128073 creator A5044613951 @default.
• W2946128073 creator A5052658465 @default.
• W2946128073 creator A5055055894 @default.
• W2946128073 creator A5060949051 @default.
• W2946128073 creator A5068824818 @default.
• W2946128073 creator A5075296860 @default.
• W2946128073 creator A5081735541 @default.
• W2946128073 creator A5086249998 @default.
• W2946128073 creator A5089962252 @default.
• W2946128073 creator A5091727687 @default.
• W2946128073 date "2019-08-15" @default.
• W2946128073 modified "2023-10-03" @default.
• W2946128073 title "Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors" @default.
• W2946128073 cites W1563019250 @default.
• W2946128073 cites W1974519242 @default.
• W2946128073 cites W2017452957 @default.
• W2946128073 cites W2030174339 @default.
• W2946128073 cites W2031541885 @default.
• W2946128073 cites W2044293524 @default.
• W2946128073 cites W2072564984 @default.
• W2946128073 cites W2113727201 @default.
• W2946128073 cites W2123621576 @default.
• W2946128073 cites W2139560553 @default.
• W2946128073 cites W2147893730 @default.
• W2946128073 cites W2159060826 @default.
• W2946128073 cites W2161608625 @default.
• W2946128073 cites W2169752008 @default.
• W2946128073 cites W2462649057 @default.
• W2946128073 cites W2550856922 @default.
• W2946128073 cites W2566505805 @default.
• W2946128073 cites W2595713273 @default.
• W2946128073 cites W2597742783 @default.
• W2946128073 cites W2605790099 @default.
• W2946128073 cites W2625547485 @default.
• W2946128073 cites W2671996661 @default.
• W2946128073 cites W2763670669 @default.
• W2946128073 cites W2889657308 @default.
• W2946128073 cites W4313635027 @default.
• W2946128073 doi "https://doi.org/10.1158/1078-0432.ccr-18-3334" @default.
• W2946128073 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31088831" @default.
• W2946128073 hasPublicationYear "2019" @default.
• W2946128073 type Work @default.
• W2946128073 sameAs 2946128073 @default.
• W2946128073 citedByCount "162" @default.
• W2946128073 countsByYear W29461280732019 @default.
• W2946128073 countsByYear W29461280732020 @default.
• W2946128073 countsByYear W29461280732021 @default.
• W2946128073 countsByYear W29461280732022 @default.
• W2946128073 countsByYear W29461280732023 @default.
• W2946128073 crossrefType "journal-article" @default.
• W2946128073 hasAuthorship W2946128073A5000961519 @default.
• W2946128073 hasAuthorship W2946128073A5000978310 @default.
• W2946128073 hasAuthorship W2946128073A5006299989 @default.
• W2946128073 hasAuthorship W2946128073A5006620245 @default.
• W2946128073 hasAuthorship W2946128073A5021392198 @default.
• W2946128073 hasAuthorship W2946128073A5024388671 @default.
• W2946128073 hasAuthorship W2946128073A5028976895 @default.
• W2946128073 hasAuthorship W2946128073A5029434394 @default.
• W2946128073 hasAuthorship W2946128073A5031446684 @default.
• W2946128073 hasAuthorship W2946128073A5044613951 @default.
• W2946128073 hasAuthorship W2946128073A5052658465 @default.
• W2946128073 hasAuthorship W2946128073A5055055894 @default.
• W2946128073 hasAuthorship W2946128073A5060949051 @default.
• W2946128073 hasAuthorship W2946128073A5068824818 @default.
• W2946128073 hasAuthorship W2946128073A5075296860 @default.
• W2946128073 hasAuthorship W2946128073A5081735541 @default.
• W2946128073 hasAuthorship W2946128073A5086249998 @default.
• W2946128073 hasAuthorship W2946128073A5089962252 @default.
• W2946128073 hasAuthorship W2946128073A5091727687 @default.
• W2946128073 hasConcept C126322002 @default.
• W2946128073 hasConcept C126894567 @default.
• W2946128073 hasConcept C142424586 @default.
• W2946128073 hasConcept C143998085 @default.
• W2946128073 hasConcept C170493617 @default.
• W2946128073 hasConcept C197934379 @default.
• W2946128073 hasConcept C2776036575 @default.
• W2946128073 hasConcept C2778375690 @default.
• W2946128073 hasConcept C2778653478 @default.
• W2946128073 hasConcept C71924100 @default.
• W2946128073 hasConcept C74373430 @default.
• W2946128073 hasConcept C82867764 @default.
• W2946128073 hasConcept C86803240 @default.
• W2946128073 hasConcept C87355193 @default.
• W2946128073 hasConcept C90924648 @default.
• W2946128073 hasConceptScore W2946128073C126322002 @default.
• W2946128073 hasConceptScore W2946128073C126894567 @default.
• W2946128073 hasConceptScore W2946128073C142424586 @default.

• next